

1 **Long-term effects of increased adoption of artemisinin combination therapies** 2 **in Burkina Faso**

3 Robert J. Zupko^{1*}, Tran Dang Nguyen¹, Anyirékun Fabrice Somé², Thu Nguyen-Anh Tran¹, Jaline
4 Gerardin³, Patrick Dudas⁴, Dang Duy Hoang Giang⁵, Amy Wesolowski⁶, Jean-Bosco Ouédraogo⁷, Maciej
5 F. Boni¹

6
7 ¹ Center for Infectious Disease Dynamics, Department of Biology, Pennsylvania State University,
8 University Park, PA, USA

9 ² Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo Dioulasso, Burkina
10 Faso

11 ³ Department of Preventive Medicine and Institute for Global Health, Northwestern University, Chicago,
12 IL, USA

13 ⁴ Institute for Computational and Data Sciences, Pennsylvania State University, University Park, PA,
14 USA

15 ⁵ Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Hospital for
16 Tropical Diseases, Ho Chi Minh City, Vietnam

17 ⁶ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

18 ⁷ Institut de Recherche en Sciences de La Santé, Bobo-Dioulasso, Burkina Faso

19 * Corresponding Author, rbz5100@psu.edu

20

21 Date of this Draft: Aug 19, 2021

22 Word Count: 4865

23

24 Keywords: Anti-Malarial Drug Resistance, Artemisinin Combination Therapy, Burkina Faso, Malaria

25

26 **Abstract**

27 Artemisinin combination therapies (ACTs) are the WHO-recommended first-line therapies for
28 uncomplicated *Plasmodium falciparum* malaria. The emergence and spread of artemisinin-resistant
29 genotypes is a major global public health concern. To explore how the increased adoption of ACTs may
30 affect the high-burden high-impact malaria setting of Burkina Faso, we added spatial structure to a validated
31 individual-based stochastic model of *P. falciparum* transmission and evaluated long-term effects of
32 increased ACT use. We explored how *de novo* emergence of artemisinin-resistant genotypes may occur
33 under scenarios in which private-market drugs are eliminated or multiple first-line therapies (MFT) are
34 deployed. We found that elimination of private market drugs would reduce the long-run treatment failures.
35 An MFT policy with equal deployment of artemether-lumefantrine (AL) and dihydroartemisinin-
36 piperaquine (DHA-PPQ) may accelerate near-term drug resistance and treatment failure rates, due to early
37 failure and substantially reduced treatment efficacy resulting from piperaquine-resistant genotypes. A
38 rebalanced MFT approach (90% AL, 10% DHA-PPQ) results in better long-term outcomes than using AL
39 alone but may be difficult to implement in practice.

40

41 **Introduction**

42 Despite the United Nations' Millennium Development Goals leading to substantial reductions in the global
43 burden of infectious disease, malaria remains a serious public health risk in many parts of Africa, Asia, and
44 South America. *Plasmodium falciparum* malaria remains holoendemic in at least eleven countries, mainly
45 in western and central Africa, and these countries have recently come under a WHO grouping called high-
46 burden high-impact (HBHI) which recognizes that the most severely affected malaria-endemic countries
47 will require additional resources and greater policy imagination (WHO 2019, p. 24). The two primary
48 concerns in HBHI countries are high and widespread vectorial capacity and insufficient access to high-
49 efficacy antimalarial therapies. Traditionally, drug-resistance concerns in holoendemic settings are of
50 secondary importance because of the historical relationship between low-transmission regions and drug-
51 resistance emergence and the relatively weak selection pressure imposed by lower levels of antimalarial
52 use.

53 Artemisinin-resistant phenotypes were first identified in 2007-2008 in western Cambodia and have
54 since been linked to a number of point mutations in the *P. falciparum kelch13* gene (Ariey et al. 2014;
55 Ashley et al. 2014). Since the identification of these molecular markers, artemisinin resistance has been
56 found in Bangladesh, Guyana, Laos, Myanmar, Papua-New Guinea, Thailand, Rwanda, and Vietnam
57 (Ashley et al. 2014; Chenet et al., 2015; Mathieu et al. 2020; Miotto et al. 2020; WHO 2019; Uwimana et
58 al., 2020). Artemisinin-resistant parasites can either be imported from other regions (e.g., spread across
59 Southeast Asia), or they may emerge independently as in Guyana, Papua-New Guinea, and Rwanda (Ashley
60 et al. 2014; Chenet et al., 2015; Uwimana et al., 2020). This raises the possibility that HBHI countries may
61 be at risk artemisinin resistance appearing due to *de novo* emergence or the importation of a resistant
62 parasite.

63 Burkina Faso has been identified as an HBHI nation and malaria remains the leading cause of
64 hospitalization in the general population (45.8% of all hospitalizations) as well as for children under five
65 (48.2%) (WHO 2019; Ministère de la Santé 2020, p. 40). Malaria transmission is endemic throughout the
66 country and seasonal transmission is aligned with the rainfall patterns of the three seasonal zones. The
67 northern Sahelian region has a short-peak transmission season of approximately three months, increasing
68 to four months in the central Sudano-Sahelian region, and reaching about five months in the southwestern
69 Sudanian region (Ministère de la Santé 2016, p. 24). Artemisinin combination therapies have been in use
70 in Burkina Faso since their adoption in 2005, resulting in significant reductions in malaria prevalence
71 (Ministère de la Santé 2016, p. 28; Weiss et al. 2019; WHO 2019). Alongside increasing access to ACTs,
72 local public health officials have also credited broader adoption of insecticide-treated mosquito nets (ITNs),
73 higher levels of indoor residual spraying (IRS), and new programs in intermittent preventive treatment of
74 pregnant women (IPTp) and seasonal malaria chemoprevention (SMC) (PMI 2019). The national goal for

75 SMC is that it be provided to all children aged 3-59 months by 2020 (PMI 2019). Currently, there are no
76 signs of artemisinin resistance in Burkina Faso, as no molecular markers have been observed. However,
77 recent studies suggest that first-line ACT therapies may have reduced efficacy in children aged 6-59 months
78 (Gansané et al. 2021), and detectable parasitemia 72 hours after treatment with artemether–lumefantrine
79 (AL) has been observed (Beshir et al. 2021).

80 The widespread adoption of ACTs has led to reductions in malaria prevalence in the past 10 years,
81 but the widespread use of ACTs within Burkina Faso also places selective pressure on the parasite to evolve
82 resistance. The impact that artemisinin-resistant *P. falciparum* would have in Burkina Faso is currently
83 unknown; however, ensuring the continued efficacy of ACTs is a top priority for all national malaria control
84 programs in Africa. Accordingly, the development of spatial, individual-based stochastic models allows for
85 projections to be made as to when and where artemisinin resistant parasites may appear and how drug
86 policies may affect the evolution of drug resistance in the parasite. In this study we have modified and
87 calibrated a spatial individual-based model for Burkina Faso. This model has been used to explore two
88 broad concerns: the possible emergence or importation of artemisinin resistance under the current health
89 care regime and the impact that various drug policy interventions may have on artemisinin resistance.

90

91 **Results**

92 *Baseline Configuration (de novo emergence)*

93 A previously calibrated individual-based malaria model (Nguyen et al, 2015) was parametrized to fit mean
94 Malaria Atlas Project *PfPR*₂₋₁₀ projections for Burkina Faso in 2017 on a 5km-by-5km cell (or pixel) basis
95 (Weiss et al. 2019). Individual movement was fit to recently available travel survey data for both the
96 destination and frequency (Fig. 1d) (Marshall et al. 2016; Marshall et al. 2018). When individuals in the
97 model are infected, the asexual parasite density is modeled and the levels of parasitemia and immune
98 response are used to determine symptoms occurrence and treatment seeking behavior. Individuals in the
99 model seek treatment at different rates based upon their age group: under-5 treatment rates were based upon
100 the Malaria Indicator Survey rates (INSD et al. 2018), while the over-5 treatment rates were adjusted to be
101 55% lower (relative scale) than the under-5 treatment rate to account for lower rates of treatment seeking
102 among adults (Robyn et al. 2012). Both treatment rates are increased by 3% each model year to account for
103 the expected increase in access to treatment over time (Bennett et al., 2017). Therapies given to individuals
104 use a simplified single-compartment pharmacokinetic/pharmacodynamic (PK/PD) model with PK/PD
105 parameters calibrated to reflect the expected efficacies of specific antimalarial compounds on particular *P.*
106 *falciparum* genotypes (Nguyen et al. 2021), and parasitemia levels after 28 days are used to determine
107 treatment failure.

108 As a baseline scenario we examined the *de novo* emergence of the *pfkelch13* 580Y allele in the
109 context of the existing national treatments: recommended first-line therapies of AL or dihydroartemisinin-
110 piperaquine (DHA-PPQ), artesunate (AS) or quinine for severe malaria, and private-market treatments
111 artesunate-mefloquine (ASMQ), amodiaquine (AQ), chloroquine (CQ), and sulfadoxine-pyrimethamine
112 (SP) (INSD et al., 2018). The model calibration and baseline status quo scenario accounted for the use of
113 artesunate–amodiaquine (ASAQ), but post-2018 ASAQ usage was proportionally allocated to AL and
114 DHA-PPQ usage due to the planned phase-out of ASAQ by June 2018 (PMI 2019). The *de novo* emergence
115 rate of 580Y alleles – an unknown value in general contexts – was set using a previous model alignment
116 exercise (Watson et al 2021); under this parameterization, 580Y alleles progress from 0.00 to 0.01 allele
117 frequency in seven years, assuming 10% $PfPR_{2-10}$ and 40% drug coverage with DHA-PPQ only.

118 Under this baseline parameterization, we found that by model year 2038 the national median
119 frequency of 580Y would be 0.048 (IQR 0.046 – 0.052), with a treatment failure rate of 11.57% (IQR
120 11.52% - 11.62%), although on a local (i.e., cellular or pixel) basis the values may be higher or lower,
121 depend strongly on the stochasticity of initial emergence (Fig. 2). Furthermore, on a provincial basis, the
122 580Y allele frequency reaches a median of 0.0569 (IQR 0.0512 – 0.0634); with provinces that have a high
123 prevalence and moderate to high ACT usage at higher risk of accelerated mutation fixation. The spatial
124 distribution of 580Y in the model confirms that (i) emergence is stochastic, and (ii) high treatment coverage
125 coupled with either high prevalence or permanent transmission contributes to acceleration of local selection
126 for the 580Y mutation (or another *kelch13* mutation with similar effect on artemisinin efficacy).
127 Accordingly, the highest frequencies of 580Y under the baseline parametrization occur in the south-western
128 Sudanian climate range (i.e., permanent transmission and high treatment coverage) and northern regions
129 (i.e., high prevalence and high treatment coverage) of Burkina Faso.

130

131 *Drug Policy Interventions*

132 The distribution of treatments used in Burkina Faso suggests two possible drug policy interventions
133 affecting the use of private market drugs and the deployment of nationally recommended first-line therapies.
134 First, private-market drugs account for about 16.8% of treatments for febrile illness, with AQ monotherapy
135 accounting for 73.8% of private-market treatments (12.4% of national treatments) (INSD et al., 2018).
136 Reduction or elimination of private-market purchases would ensure that individuals are more likely to
137 receive a recommended first-line therapy (always an ACT) with higher efficacy. Second, it may be possible
138 to shift from AL as the primary single first-line therapy to the use of multiple first-line therapies (MFT) in
139 which AL and DHA-PPQ are prescribed, distributed, and used in approximately equal amounts. The use of
140 MFT may delay the emergence and spread of drug resistance and improve long-run clinical outcomes (Boni
141 et al. 2008). To examine these two drug policy interventions, the baseline parametrization of current

142 treatment distribution was modified to include private-market elimination, MFT, or both. We investigated
143 scenarios where immediate or gradual (phased in over ten years) implementation of MFT and private market
144 elimination occurred (see Supplemental Table 1).

145 As expected, a focus solely upon the elimination of the private market results in an increase in the
146 frequency of 580Y due to the resulting increase in ACT usage (Fig. 3). Under the rapid elimination scenario,
147 the national median frequency of 580Y rises to 0.106 (IQR 0.010 - 0.113) by model year 2038, while under
148 a ten-year elimination strategy median 580Y frequency in 2038 is slightly lower at 0.085 (IRQ 0.081 -
149 0.091). Elimination of the private market has a favorable outcome on treatment failures due to their
150 reduction in relation to the baseline scenario, with a rapid elimination resulting in a failure rate of 8.88%
151 (IRQ 8.80% - 8.97%) in model year 2038 and a ten-year phase out resulting in a slightly lower rate of 8.58%
152 (IRQ 8.53% - 8.65%). This reduction in treatment failures in comparison to the baseline configuration (23%
153 reduction for rapid elimination, and 26% reduction for ten-year phase-out), despite the higher 580Y
154 frequency, highlights the value in ensuring that individuals use highly efficacious treatments when
155 presenting with malaria. Note that the model predicts that the intermediate option (10-year phase-out) is the
156 best long-term approach for reducing treatment failures, highlighting the combined effects of artemisinin-
157 resistance evolution and high-efficacy treatment access that need to be considered in long-term drug-
158 resistance planning.

159 In contrast to the elimination of the private market, the model suggests that the introduction of MFT
160 with an equal distribution of AL and DHA-PPQ would have a negative effect on treatment failure rates due
161 to a more rapid acceleration in 580Y frequency (Fig. 4), driven primarily by DHA-PPQ. When an MFT
162 strategy with AL and DHA-PPQ is implemented without elimination of the private market, treatment
163 failures increase to a national median of 21.52% (IQR 21.27% – 21.66%) by model year 2038, and 19.47%
164 (IQR 19.31% – 19.65%) when MFT is phased in over ten years. While the frequency of 580Y is high under
165 both scenarios, reaching a national median of 0.294 (IQR 0.283 – 0.307) by model year 2038 with rapid
166 adoption and 0.189 (IQR 0.182 – 0.202) with a ten-year introduction, it is insufficient to account for the
167 treatment failure rate alone suggesting multiple factors at play. The rate of treatment failures is accelerated
168 when MFT is coupled with private market elimination. Under a rapid private market elimination scenario,
169 coupled with the immediate adoption of MFT, the resulting national median treatment failure rate in model
170 year 2038 of 24.92% (IQR 24.58% - 25.14%) and 580Y frequency of 0.532 (0.513 – 0.545) by the end of
171 the simulation. This pattern of increased 580Y frequency is observed across all permutations of private
172 market elimination and MFT adoption rates (Table 1).

173 This adverse MFT outcome is attributable to the increased usage of DHA-PPQ as the co-equal first-
174 line therapy. Typically, MFT policies result in better long-term drug-resistance outcomes due to the
175 heterogeneous drug environments they create (Boni et al. 2008; Boni et al. 2016). However, these analyses

176 assume that all therapies distributed in an MFT policy are equally efficacious and have identical drug-
177 resistance properties. This is not the case when comparing DHA-PPQ and AL, as piperazine (PPQ)
178 resistance leads to higher levels of treatment failure when compared to lumefantrine resistance (Nguyen et
179 al. 2021). In contrast to the baseline scenario with limited DHA-PPQ usage (5.1%), or the nominal increase
180 resulting from private market elimination (6.2%), introduction of MFT results in DHA-PPQ usage in 46.1%
181 of treatments when coupled with private market elimination (Supplemental Table 1). The drug policy
182 combination of rapid private market elimination along with rapid MFT introduction results in rapid
183 frequency increase of the *plasmepsin-2,3* double-copy genotypes conferring PPQ resistance (Witkowski et
184 al. 2017). Effectively, following acquisition of PPQ resistance, the continued selective pressure of DHA
185 produces an environment that is more favorable to the development of artemisinin resistance due to the lack
186 of partner-drug killing of potentially emergent artemisinin-resistant genotypes. This is consistent with
187 recent findings that partner-drug resistance facilitates the development of primary drug (i.e., artemisinin)
188 resistance (Watson et al. 2021). The increased frequency of *plasmepsin-2,3* double-copy genotypes is
189 observable shortly after implementation of the policy in model year 2021 (Fig. 5) and is present in all
190 scenarios that implement MFT (Fig. 6).

191 To further investigate the parameters under which an MFT policy incorporating DHA-PPQ may be
192 implemented in Burkina Faso, additional scenarios were considered in the absence of a private market: the
193 use of AL as the sole first-line therapy, along with MFT combinations of AL and DHA-PPQ including a
194 range from 60% to 90% AL use (Supplemental Table 1). When AL is used as a sole first-line therapy for
195 uncomplicated malaria, the 580Y frequency reaches 0.115 (IQR 0.109 – 0.119) by model year 2038 with a
196 treatment failure rate below that of the status quo scenario of 9.16% (IQR 9.09% - 9.21%). When MFT is
197 introduced using DHA-PPQ (10% of treatments) and AL (90%) the results by model year 2038 show a
198 small reduction in the 580Y frequency (0.111, IQR 0.103 – 0.117) and treatment failure rate (9.14%, IQR
199 9.04% - 9.22%) when compared to the AL as the sole first-line therapy. However, when the usage of DHA-
200 PPQ is increased to 20% or higher, there is an increase in 580Y frequencies along with treatment failure
201 rates by model year 2038 (Table 1, Fig.7).

202

203 *Seasonal changes in alleles frequencies*

204 As in some observed field studies (Babiker et al. 2013; Ord et al. 2007), drug-resistance allele frequencies
205 in our model fluctuated with the periodicity of the transmission season (Supplemental Figure 13). This
206 effect is most pronounced in regions of Burkina Faso where there is highly seasonal transmission (e.g.,
207 northern Sahelian climate zone). In order to examine this effect, additional simulations were conducted
208 that reduced the geographic scope of the model to a single 25 sq.km cell, allowing for more model detail to
209 be captured (see Supplementary Section 8). Our simulations show an increase in the ratio of

210 symptomatic/asymptomatic individuals during the rainy season, resulting in increased evolutionary
211 pressure favoring drug resistance due to a higher proportion of *P. falciparum* infections being treated. The
212 reason for the increase in the symptomatic/asymptomatic ratio during peak transmission likely results from
213 several factors, namely, (i) a lower population-average level of immunity at the beginning of the high
214 transmission season, (ii) possibility for multiple bites and repeat symptoms for individuals with low
215 immunity, and (iii) correlation between low biting attractiveness and low immunity which will skew the
216 ratio of bites on immunes/non-immunes from low to high transmission periods. Although the seasonal trend
217 in drug-resistance frequency was up during the rainy season and down or flat during the dry season, the
218 overall long-term trend remained upward with increasing drug resistance.

219

220 **Discussion**

221 While the evolution of drug resistance by the *P. falciparum* parasite is a pressing concern, in HBHI
222 countries drug resistance evolution is secondary to the need to increase access to and usage of ACTs. Once
223 access to ACTs is near universal, more attention should be turned towards the future impacts of drug
224 resistance. As noted by Valle et al (2016), the spatial distribution of drug access and disease burden cannot
225 be presumed to be uniform, and this heterogeneity will have onward effects on which areas need more focus
226 on basic public health access versus drug-resistance management. As policy makers need to work within
227 their local constraints when designing national drug policies, the overall national-scale timeline of the
228 emergence and spread of drug resistance should still be the main focal point in the preparation and design
229 of control strategies for drug resistance.

230 Presently there are early signals of ACT treatment failures starting to appear in Burkina Faso (Beshir
231 et al. 2021; Gansané et al. 2021), although a genetic mechanism has not been identified, nor is it clear how
232 widespread these signals are. If these signals are confirmed to have a genetic basis, then our study suggests
233 that widespread resistance may manifest at a low level within a decade if there are no changes to drug
234 policies. While the present drug mixture in Burkina Faso results in a low amount of evolutionary pressure
235 on the parasite (specifically, pressure on artemisinin resistance via the 580Y allele), the rates of ACT usage
236 are likely to increase in the future (Supplemental Section 6), indicating that evolutionary pressure will
237 strengthen as access to ACTs increases and other interventions are implemented. Given the negative impact
238 the private market has upon the overall treatment failure rate, policy makers may wish to explore ways to
239 reduce or eliminate the use of private market drugs. Doing so would ensure broader use of highly efficacious
240 ACTs and have a minimal impact upon the projected rise of drug resistance given the current drug mixture
241 in Burkina Faso.

242 This study highlights the need for ACT partner-drug resistance awareness, particularly when partner-
243 drug resistance has already been identified (Leroy et al. 2019). In the long term, drug resistance is expected

244 to evolve in all scenarios where population-level drug-use is sufficiently high, but resistance does not imply
245 complete loss of efficacy. For example, in the case of lumefantrine, the efficacy of AL remains high at 89%
246 on lumefantrine-resistant genotypes (Nguyen et al. 2021); however, DHA-PPQ efficacy drops to 77% when
247 PPQ resistant parasites are present (Nguyen et al. 2021). Ultimately, the partner drug moderates the pace at
248 which artemisinin resistance can emerge, rapid acquisition of resistance to the partner drug results in an
249 acceleration of artemisinin resistance due to usage of ACT as a ‘de facto monotherapy’ because of low
250 efficacy of the partner drug .

251 Despite the increase in drug resistance and treatment failures under a balanced MFT approach,
252 elimination of the private market (with or without an MFT) may offer policy makers more flexibility. If
253 MFT is not implemented, then this study suggests that the overall rate of treatment failures will go down as
254 the public switches to more efficacious treatments. While the selective pressure on the parasite will increase,
255 an increase in selective pressure is assumed regardless of intervention due to efforts to increase access to
256 ACTs. Furthermore, this study suggests that the timeframe for gaining benefits from private market
257 elimination may be quite broad. While elimination is unlikely outside of a model, phasing the private market
258 over ten years may be achievable.

259 Any modeling exercise is dependent upon assumptions and simplifications that may impact the results.
260 The primary limitation of this model is that it does not account the 2018 introduction of a broad SMC
261 program intended to reach all children under-5 in Burkina Faso (PMI 2019). Given the recency of this broad
262 approach to the program, limited data is available to calibrate model parameters accurately. The exclusion
263 of SMC in our analysis likely results in a simulated prevalence that is higher than what is likely to be
264 observed in the field. However, this needs to be moderated against the unknown impacts of the ongoing
265 COVID-19 pandemic, which may impact malaria control programs and possibly lead to higher $PfPR_{2-10}$
266 than what was used for model calibration, although the real impacts may not be quantifiable for several
267 years (Heuschen et al. 2021; Weiss et al., 2020).

268 While the mutation rate used by the simulation is based upon an accepted alignment based on the
269 observed pattern of *kelch13* evolution in SE Asia over the past two decades (Watson et al. 2021), the true
270 mutation rate may be faster or slower. This is a common limitation of mathematical models of evolution
271 since values for mutation parameters are difficult to estimate during short periods of observation (Carrella
272 2021; Willem et al. 2017). As such, the mutation rates result in simulation outputs wherein the relative
273 results can be compared (i.e., private market elimination versus status quo) but the absolute values are
274 susceptible to error if the mutation rate assumption is incorrect. Another limitation is the simplified nature
275 of the pharmacokinetic model that is being used. While an individual multi-compartment model for each
276 compounded incorporated in the simulation would be the best approach (Simpson et al. 2014), the
277 complexity of implementation was balanced against the objectives of this simulation, namely, to ensure that

278 the parasite killing rate and evolutionary pressure resulting from treatment was consistent with the 24-hour
279 timestep used by the simulation. It is not known how model misspecification of PK/PD dynamics on a
280 minute/hour timescale affects long-term evolutionary outcome years or decades into the future.

281 It has been well established that asymptomatic individuals with *P. falciparum* play an important role in
282 the propagation of the parasite between rainy seasons (Andrade et al. 2020); however, the impact that this
283 has upon the evolution of drug resistance has not been well established. The seasonal periodicity of
284 resistance markers that appeared in this simulation, in conjunction with previous results concerning the role
285 that seasonality and asymptomatic carriers may play in the selection of drug-sensitive or -resistant parasites
286 (Andrade et al. 2020; Babiker et al. 2013), suggests that more work is needed to understand how seasonal
287 transmission affects selection. Improved simulation approaches will be necessary to assist policymakers in
288 addressing the critical question of when ACTs will need to be replaced? While ACTs remain highly
289 effective in Africa, this study, along with recent reports on treatment failure (Beshir et al. 2021; Gansané et
290 al. 2021; Uwimana et al. 2020) suggest that we may be starting to enter a period of emerging artemisinin
291 resistance and an end to the current “calm before the storm” suggested by Conrad and Rosenthal (2019).
292 This transition is inevitable. ACT access is likely to increase in the coming years, reducing case numbers
293 but increasing the selection pressure of artemisinin-resistant genotypes. Preparation, prevention, and
294 preemption during this high-risk period for drug-resistance emergence will be key to ensuring that first-line
295 treatment against *P. falciparum* continue working at high efficacy in the 2020s and 2030s.

296

297 **Methods**

298 *Model Design*

299 This study builds upon the individual-based stochastic model of malaria transmission previously developed
300 by Nguyen et al. (2015) to incorporate space and geography. As with the initial model, individuals have
301 attributes such as age, attractiveness to mosquitos, level of parasitemia, and so forth. In addition to the new
302 of spatial components, the individual infection model was revised to incorporate a more realistic sporozoite
303 challenge (see Supplemental Materials 5.1). The spatial component of the model allows for variables such
304 as climate, heterogeneous access to treatment, and individual movement to be incorporated into the
305 simulation.

306 In order to calibrate the model for Burkina Faso, we started by first preparing geographic
307 information system (GIS) raster files for the country at the scale of 5km-by-5km pixels (or cells). These
308 cells in turn contain the starting population of the model, approximately 3.6 million individuals or about
309 25% of the 2007 population of Burkina Faso, which are distributed based upon the population density of
310 the country (WorldPop 2018). This population is allowed to grow and move throughout the simulated
311 landscape, carrying any parasite colonies that they may be infected with as well. Data is collected from the

312 model starting in the simulated year 2018 which approximates the most recent Malaria Indicator Survey for
313 Burkina Faso used for model calibration. Simulation runs using 100% versus 25% of the population size
314 are not found to be qualitatively different.

315 The primary measure for artemisinin resistance in the model is the frequency of the 580Y mutation
316 in *pfkelch13*. Upon model initialization the frequency of 580Y is zero and following the introduction of
317 widespread ACT usage, the locus is allowed to mutate with a probability of 0.001983 per infection, where
318 the mutation rate is based upon a model alignment exercises for the time to reach 1% allele frequency of
319 580Y (Watson et al. 2021). Other genetic makers associated with drug resistance here *plasmepsin-2,3*
320 double copy, *pfmdr1* double copy, *pfprt-k76*, *pfmdr1-N86*, *pfmdr1-I84F*) are included in the model and
321 operate in a similar fashion to 580Y with the model initialized with the sensitive genotype. For each
322 scenario, a total of 50 replicates are performed to ensure sufficient coverage of outlier simulation results.

323 To evaluate the impact that various drug policies have on treatment, the simulation tracks the
324 number of clinical cases (i.e., individuals with clinical symptoms), the reported number of cases (i.e.,
325 individuals with clinical symptoms receiving medical care), treatment failures (i.e., individuals with clinical
326 symptoms for whom the prescribed treatment was not effective), and the number of individuals with clinical
327 symptoms who did not seek treatment. Additionally, the genotype of the parasite, or parasites in the case
328 of a multiclonal infection, is tracked across all individuals in the model.

329

330 *Model Validation*

331 The spatial model of Burkina Faso has 10,936 5km-by-5km (25 sq.km) pixels with a population of at least
332 one individual at model initialization, allowing for comparisons to the annual mean $PfPR_{2-10}$ estimates for
333 nominal year 2017, using the first data set released by the Malaria Atlas Project (Weiss et al. 2019). Each
334 pixel is assigned a transmission parameter β which corresponds, approximately, to the local force of
335 infection or vectorial capacity at that location. Individual pixel $PfPR$ s were calibrated by finding a β that
336 results in the appropriate annual mean $PfPR_{2-10}$ given a cell's population size, treatment coverage, seasonal
337 transmission pattern, and reference $PfPR_{2-10}$. The predicted population weighted annual mean $PfPR_{2-10}$
338 values for each cell were then aggregated to the province level for comparison to the Malaria Atlas Project
339 values (Figure 1a). Individual movement was added into the model by using a modified gravity model
340 (Zupko et al. 2021) that was re-fit from data presented in Marshall et al (2016, 2018). Pixel-level and
341 province-level $PfPR_{2-10}$ values were evaluated to ensure that movement did not have too large of an overall
342 effect on $PfPR_{2-10}$ trends. All individual movement presumes an eventual return to the original cell of the
343 individual (i.e., round trips only), although the length of the trip is variable and may involve multiple stops.
344 Province-level simulated $PfPR_{2-10}$ values, with the full model (including movement), are compared to
345 reference $PfPR_{2-10}$ data in Figure 1. All mosquito bites in the simulation are presumed to be infectious and

346 the individual is infected with the parasite if they are unable to resist the initial exposure to the sporozoite
347 (see Supplemental Information, Section 5.1).

348

349 *Scenarios Comparisons*

350 All studies evaluated use a baseline business-as-usual configuration for Burkina Faso, in which the model
351 is parameterized to match the Malaria Atlas Project prevalence in 2017 (Weiss et al. 2019). Drug coverage
352 (i.e., the percentage of malaria-positive febrile individuals who are able to obtain drug treatment and choose
353 to do so) for 2017 is set to be province-specific, based on data from a 2018 malaria indicator survey (INSD
354 et al. 2018). For symptomatic individuals that receive antimalarial treatment, the distribution of drugs
355 used/prescribed is taken from this malaria indicator survey; however, since distribution is known only at a
356 national level it is applied to the province-level drug coverage to get a final table of province-level treatment
357 distributions (or lack thereof). At a national level, 16.8% of individuals use antimalarials purchased in the
358 private market and 83.2% receive an artemisinin combination therapy in the public-sector (91.6% AL, 6.6%
359 ASAQ, 1.8% DHA-PPQ) for uncomplicated malaria in non-pregnant individuals. To account for the phase
360 out of ASAQ, the 6.6% was proportionally redistributed for the final business-as-usual public-sector
361 treatment mix (93.3% AL, 6.7% DHA-PPQ). Access to treatment is assumed to go up every year in each
362 province by about 3% starting with model year 2019 as the first year of improved access.

363 Building upon the business-as-usual configuration, two primary scenarios were considered:
364 elimination of private market drugs, and introduction of MFT. These two core scenarios were then
365 considered in the context of immediate implementation or ten-year phased implementation with
366 adjustments to the drug distribution occurring one per model year. For private market elimination scenarios,
367 the reduction in private market treatment usage is proportionality distributed every year to the public market
368 treatment included in the study. Likewise, for the MFT scenario, a goal of an even distribution of AL and
369 DHA-PPQ is assumed, and the usage of AL is reduced on an annual basis and allocated to DHA-PPQ usage
370 until an even distribution was reached. The various permutations of private market elimination, MFT, and
371 implementation timelines the made up eight of the thirteen drug policy scenarios examined (see
372 Supplemental Information, Table 6). The remaining five drug policy scenarios were designed to evaluate
373 the impact of various MFT mixes of AL and DHA-PPQ ranging from 100% AL to 50% AL by 10%
374 reductions in AL usage. Since the intent of these scenarios is to evaluate the impact of the MFT drug mixture
375 on the emergence of resistance, rapid private market elimination was used for all of them.

376

377 **Data availability**

378 Spatial raster files used in the simulation and long with intermediary files used for analysis and plot
379 generation can be found at [https://github.com/bonilab/malariaibm-spatial-BurkinaFaso-](https://github.com/bonilab/malariaibm-spatial-BurkinaFaso-2021/tree/main/Data)
380 [2021/tree/main/Data](https://github.com/bonilab/malariaibm-spatial-BurkinaFaso-2021/tree/main/Data)

381
382 **Code availability**

383 The source code for the base mathematical model and analysis specific to this manuscript
384 <https://github.com/bonilab/malariaibm-spatial-BurkinaFaso-2021>

385
386 **Acknowledgements**

387 This work was supported by the National Institutes of Health (R01AI153355) and the Bill & Melinda Gates
388 Foundation grants OPP159934 to the University of Washington and INV-005517 to Pennsylvania State
389 University. Simulations described in this study were performed on the Pennsylvania State University's
390 Institute for Computational and Data Sciences' Roar supercomputer.

391
392 **Author Contributions**

393 RJZ developed the model's spatial framework, fit the model to movement and epidemiological data,
394 conducted the simulation studies, and drafted the manuscript. RJZ and TDN integrated the spatial
395 framework into the previous model version and carried out epidemiological validation analyses. AFS, JG,
396 AW, J-BO guided the calibration of the model's epidemiological and movement behaviors. TNAT
397 parameterized the model's partial drug-resistance phenotypes and evaluated these phenotypes' trajectories
398 in the model simulations. PD developed visualizations for model outcomes. DDHG developed a pilot model
399 for testing. RJZ and MFB designed the simulation study and edited the manuscript. All authors read and
400 approved the final version of the manuscript.

401
402 **References**

- 403 Andrade, C. M., Fleckenstein, H., Thomson-Luque, R., Doumbo, S., Lima, N. F., Anderson, C., Hibbert, J.,
404 Hopp, C. S., Tran, T. M., Li, S., Niangaly, M., Cisse, H., Doumtabe, D., Skinner, J., Sturdevant, D.,
405 Ricklefs, S., Virtaneva, K., Asghar, M., Homann, M. V., ... Portugal, S. (2020). Increased circulation
406 time of *Plasmodium falciparum* underlies persistent asymptomatic infection in the dry season.
407 *Nature Medicine*, 26(12), 1929–1940. <https://doi.org/10.1038/s41591-020-1084-0>
- 408 Arie, F., Witkowski, B., Amaratunga, C., Beghain, J., Langlois, A.-C., Khim, N., Kim, S., Duru, V., Bouchier,
409 C., Ma, L., Lim, P., Leang, R., Duong, S., Sreng, S., Suon, S., Chuor, C. M., Bout, D. M., Ménard, S.,
410 Rogers, W. O., ... Ménard, D. (2014). A molecular marker of artemisinin-resistant *Plasmodium*
411 *falciparum* malaria. *Nature*, 505(7481), 50–55. <https://doi.org/10.1038/nature12876>
- 412 Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M.,
413 Mao, S., Sam, B., Sopha, C., Chuor, C. M., Nguon, C., Sovannaroeth, S., Pukrittayakamee, S.,
414 Jittamala, P., Chotivanich, K., Chutasmit, K., Suchatsoonthorn, C., ... White, N. J. (2014). Spread of

- 415 Artemisinin Resistance in Plasmodium falciparum Malaria. *New England Journal of Medicine*,
416 371(5), 411–423. <https://doi.org/10.1056/NEJMoa1314981>
- 417 Babiker, H. A., Gadalla, A. A. H., & Ranford-Cartwright, L. C. (2013). The role of asymptomatic P.
418 falciparum parasitaemia in the evolution of antimalarial drug resistance in areas of seasonal
419 transmission. *Drug Resistance Updates*, 16(1), 1–9. <https://doi.org/10.1016/j.drup.2013.02.001>
- 420 Bennett, A., Bisanzio, D., Yukich, J. O., Mappin, B., Fergus, C. A., Lynch, M., Cibulskis, R. E., Bhatt, S.,
421 Weiss, D. J., Cameron, E., Gething, P. W., & Eisele, T. P. (2017). Population coverage of artemisinin-
422 based combination treatment in children younger than 5 years with fever and Plasmodium
423 falciparum infection in Africa, 2003–2015: A modelling study using data from national surveys. *The*
424 *Lancet Global Health*, 5(4), e418–e427. [https://doi.org/10.1016/S2214-109X\(17\)30076-1](https://doi.org/10.1016/S2214-109X(17)30076-1)
- 425 Beogo, I., Huang, N., Drabo, M. K., & Yé, Y. (2016). Malaria related care-seeking-behaviour and
426 expenditures in urban settings: A household survey in Ouagadougou, Burkina Faso. *Acta Tropica*,
427 160, 78–85. <https://doi.org/10.1016/j.actatropica.2016.03.033>
- 428 Beshir, K. B., Diallo, N., Somé, F. A., Sombie, S., Zongo, I., Fofana, B., Traore, A., Dama, S., Bamadio, A.,
429 Traore, O. B., Coulibaly, S. A., Maurice, O. S., Diarra, A., Kaboré, J. M., Kodio, A., Togo, A. H., Dara,
430 N., Coulibaly, M., Dao, F., ... Sutherland, C. J. (n.d.). Persistent sub-microscopic Plasmodium
431 falciparum parasitaemia 72 hours after treatment with artemether-lumefantrine predicts 42-day
432 treatment failure in Mali and Burkina Faso. *Antimicrobial Agents and Chemotherapy*, 0(ja),
433 AAC.00873-21. <https://doi.org/10.1128/AAC.00873-21>
- 434 Boni, M. F., Smith, D. L., & Laxminarayan, R. (2008). Benefits of using multiple first-line therapies against
435 malaria. *Proceedings of the National Academy of Sciences*, 105(37), 14216.
436 <https://doi.org/10.1073/pnas.0804628105>
- 437 Boni, M. F., White, N. J., & Baird, J. K. (2016). The Community As the Patient in Malaria-Endemic Areas:
438 Preempting Drug Resistance with Multiple First-Line Therapies. *PLOS Medicine*, 13(3), e1001984.
439 <https://doi.org/10.1371/journal.pmed.1001984>
- 440 Carrella, E. (2021). No Free Lunch when Estimating Simulation Parameters. *Journal of Artificial Societies*
441 *and Social Simulation*, 24(2), 7. <https://doi.org/10.18564/jasss.4572>
- 442 Chenet, S. M., Akinyi Okoth, S., Huber, C. S., Chandrabose, J., Lucchi, N. W., Talundzic, E., Krishnalall, K.,
443 Ceron, N., Musset, L., Macedo de Oliveira, A., Venkatesan, M., Rahman, R., Barnwell, J. W., &
444 Udhayakumar, V. (2015). Independent Emergence of the Plasmodium falciparum Kelch Propeller
445 Domain Mutant Allele C580Y in Guyana. *The Journal of Infectious Diseases*, 213(9), 1472–1475.
446 <https://doi.org/10.1093/infdis/jiv752>
- 447 Conrad, M. D., & Rosenthal, P. J. (2019). Antimalarial drug resistance in Africa: The calm before the
448 storm? *The Lancet Infectious Diseases*, 19(10), e338–e351. [https://doi.org/10.1016/S1473-3099\(19\)30261-0](https://doi.org/10.1016/S1473-3099(19)30261-0)
- 450 Gansané, A., Moriarty, L. F., Ménard, D., Yerbanga, I., Ouedraogo, E., Sondo, P., Kinda, R., Tarama, C.,
451 Soulama, E., Tapsoba, M., Kangoye, D., Compaore, C. S., Badolo, O., Dao, B., Tchwenko, S., Tinto, H.,
452 & Valea, I. (2021). Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and
453 dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018.
454 *Malaria Journal*, 20(1), 48. <https://doi.org/10.1186/s12936-021-03585-6>

- 455 Heuschen, A.-K., Lu, G., Razum, O., Abdul-Mumin, A., Sankoh, O., von Seidlein, L., D'Alessandro, U., &
456 Müller, O. (2021). Public health-relevant consequences of the COVID-19 pandemic on malaria in
457 sub-Saharan Africa: A scoping review. *Malaria Journal*, 20(1), 339. [https://doi.org/10.1186/s12936-](https://doi.org/10.1186/s12936-021-03872-2)
458 [021-03872-2](https://doi.org/10.1186/s12936-021-03872-2)
- 459 Institut National de la Statistique et de la Démographie (INSD), Programme d'Appui au Développement
460 Sanitaire (PADS), & Programme National de Lutte contre le Paludisme (PNLP) et ICF. (2018).
461 *Enquête sur les Indicateurs du Paludisme, 2017-2018* (pp. 1–159).
462 <https://www.dhsprogram.com/pubs/pdf/MIS32/MIS32.pdf>
- 463 Leroy, D., Macintyre, F., Adoke, Y., Ouoba, S., Barry, A., Mombo-Ngoma, G., Ndong Ngomo, J. M., Varo,
464 R., Dossou, Y., Tshetu, A. K., Duong, T. T., Phuc, B. Q., Laurijsens, B., Klopper, R., Khim, N., Legrand,
465 E., & Ménard, D. (2019). African isolates show a high proportion of multiple copies of the
466 *Plasmodium falciparum* plasmepsin-2 gene, a piperazine resistance marker. *Malaria Journal*,
467 18(1), 126. <https://doi.org/10.1186/s12936-019-2756-4>
- 468 Marshall, J. M., Touré, M., Ouédraogo, A. L., Ndhlovu, M., Kiware, S. S., Rezai, A., Nkhama, E., Griffin, J.
469 T., Hollingsworth, T. D., Doumbia, S., Govella, N. J., Ferguson, N. M., & Ghani, A. C. (2016). Key
470 traveller groups of relevance to spatial malaria transmission: A survey of movement patterns in
471 four sub-Saharan African countries. *Malaria Journal*, 15(1), 200. [https://doi.org/10.1186/s12936-](https://doi.org/10.1186/s12936-016-1252-3)
472 [016-1252-3](https://doi.org/10.1186/s12936-016-1252-3)
- 473 Mathieu, L. C., Cox, H., Early, A. M., Mok, S., Lazrek, Y., Paquet, J.-C., Ade, M.-P., Lucchi, N. W., Grant, Q.,
474 Udhayakumar, V., Alexandre, J. S., Demar, M., Ringwald, P., Neafsey, D. E., Fidock, D. A., & Musset,
475 L. (2020). Local emergence in Amazonia of *Plasmodium falciparum* k13 C580Y mutants associated
476 with in vitro artemisinin resistance. *eLife*, 9, e51015. <https://doi.org/10.7554/eLife.51015>
- 477 Ministère de la Santé. (2016). *Plan Strategique National de Lutte Contre le Paludisme 2016-2020* (pp. 1–
478 138). Ministère de la Santé. [http://onsp-](http://onsp-sante.bf/sites/default/files/publications/166/PSN%20%20%20%20%202016-2020%20Paludisme%2002%202017.pdf)
479 [sante.bf/sites/default/files/publications/166/PSN%20%20%20%20%202016-](http://onsp-sante.bf/sites/default/files/publications/166/PSN%20%20%20%20%202016-2020%20Paludisme%2002%202017.pdf)
480 [2020 Paludisme 20 02 2017.pdf](http://onsp-sante.bf/sites/default/files/publications/166/PSN%20%20%20%20%202016-2020%20Paludisme%2002%202017.pdf)
- 481 Ministère de la Santé. (2020). *État de Santé de la Population du Burkina Faso: Rapport 2019* (pp. 1–88).
482 https://drive.google.com/uc?export=download&id=1K-Aw5Xp5eWH-DSd_VbGT85pi84UWptpC
- 483 Miotto, O., Sekihara, M., Tachibana, S.-I., Yamauchi, M., Pearson, R. D., Amato, R., Gonçalves, S., Mehra,
484 S., Noviyanti, R., Marfurt, J., Auburn, S., Price, R. N., Mueller, I., Ikeda, M., Mori, T., Hirai, M., Tavul,
485 L., Hetzel, M. W., Laman, M., ... Mita, T. (2020). Emergence of artemisinin-resistant *Plasmodium*
486 *falciparum* with kelch13 C580Y mutations on the island of New Guinea. *PLOS Pathogens*, 16(12),
487 e1009133. <https://doi.org/10.1371/journal.ppat.1009133>
- 488 Nguyen, T. D., Olliaro, P., Dondorp, A. M., Baird, J. K., Lam, H. M., Farrar, J., Thwaites, G. E., White, N. J.,
489 & Boni, M. F. (2015). Optimum population-level use of artemisinin combination therapies: A
490 modelling study. *The Lancet Global Health*, 3(12), e758–e766. [https://doi.org/10.1016/S2214-](https://doi.org/10.1016/S2214-109X(15)00162-X)
491 [109X\(15\)00162-X](https://doi.org/10.1016/S2214-109X(15)00162-X)
- 492 Nguyen, T. D., Tran, T. N.-A., Parker, D. M., White, N. J., & Boni, M. F. (2021). Antimalarial mass drug
493 administration in large populations and the evolution of drug resistance. *BioRxiv*,
494 2021.03.08.434496. <https://doi.org/10.1101/2021.03.08.434496>
- 495 Ord, R., Alexander, N., Dunyo, S., Hallett, R., Jawara, M., Targett, G., Drakeley, C. J., & Sutherland, C. J.
496 (2007). Seasonal Carriage of *pfprt* and *pfmdr1* Alleles in Gambian *Plasmodium falciparum* Imply




- 497 Reduced Fitness of Chloroquine-Resistant Parasites. *The Journal of Infectious Diseases*, 196(11),
498 1613–1619. <https://doi.org/10.1086/522154>
- 499 President’s Malaria Initiative. (2019). *Burkina Faso Malaria Operational Plan FY 2019* (pp. 1–51).
500 [https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-](https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy19/fy-2019-burkina-faso-malaria-operational-plan.pdf?sfvrsn=3)
501 [plans/fy19/fy-2019-burkina-faso-malaria-operational-plan.pdf?sfvrsn=3](https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy19/fy-2019-burkina-faso-malaria-operational-plan.pdf?sfvrsn=3)
- 502 President’s Malaria Initiative. (2020). *Burkina Faso Malaria Operational Plan FY 2020* (pp. 1–88).
503 [https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-](https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy20/fy-2020-burkina-faso-malaria-operational-plan.pdf)
504 [plans/fy20/fy-2020-burkina-faso-malaria-operational-plan.pdf](https://www.pmi.gov/docs/default-source/default-document-library/malaria-operational-plans/fy20/fy-2020-burkina-faso-malaria-operational-plan.pdf)
- 505 Simpson, J. A., Zaloumis, S., DeLivera, A. M., Price, R. N., & McCaw, J. M. (2014). Making the Most of
506 Clinical Data: Reviewing the Role of Pharmacokinetic-Pharmacodynamic Models of Anti-malarial
507 Drugs. *The AAPS Journal*, 16(5), 962–974. <https://doi.org/10.1208/s12248-014-9647-y>
- 508 Uwimana, A., Legrand, E., Stokes, B. H., Ndikumana, J.-L. M., Warsame, M., Umulisa, N., Ngamije, D.,
509 Munyaneza, T., Mazarati, J.-B., Munguti, K., Campagne, P., Criscuolo, A., Arie, F., Murindahabi, M.,
510 Ringwald, P., Fidock, D. A., Mbituyumuremyi, A., & Menard, D. (2020). Emergence and clonal
511 expansion of in vitro artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites
512 in Rwanda. *Nature Medicine*. <https://doi.org/10.1038/s41591-020-1005-2>
- 513 Valle, D., Millar, J., & Amratia, P. (2016). Spatial heterogeneity can undermine the effectiveness of
514 country-wide test and treat policy for malaria: A case study from Burkina Faso. *Malaria Journal*,
515 15(1), 513. <https://doi.org/10.1186/s12936-016-1565-2>
- 516 Watson, O. J., Gao, B., Nguyen, T. D., Tran, T. N.-A., Penny, M. A., Smith, D. L., Okell, L., Aguas, R., & Boni,
517 M. F. (2021). Pre-existing partner-drug resistance facilitates the emergence and spread of
518 artemisinin resistance: A consensus modelling study. *BioRxiv*, 2021.04.08.437876.
519 <https://doi.org/10.1101/2021.04.08.437876>
- 520 Weiss, D. J., Bertozzi-Villa, A., Rumisha, S. F., Amratia, P., Arambepola, R., Battle, K. E., Cameron, E.,
521 Chestnutt, E., Gibson, H. S., Harris, J., Keddie, S., Millar, J. J., Rozier, J., Symons, T. L., Vargas-Ruiz, C.,
522 Hay, S. I., Smith, D. L., Alonso, P. L., Noor, A. M., ... Gething, P. W. (2020). Indirect effects of the
523 COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: A
524 geospatial modelling analysis. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-](https://doi.org/10.1016/S1473-3099(20)30700-3)
525 [3099\(20\)30700-3](https://doi.org/10.1016/S1473-3099(20)30700-3)
- 526 Weiss, D. J., Lucas, T. C. D., Nguyen, M., Nandi, A. K., Bisanzio, D., Battle, K. E., Cameron, E., Twohig, K. A.,
527 Pfeffer, D. A., Rozier, J. A., Gibson, H. S., Rao, P. C., Casey, D., Bertozzi-Villa, A., Collins, E. L.,
528 Dalrymple, U., Gray, N., Harris, J. R., Howes, R. E., ... Gething, P. W. (2019). Mapping the global
529 prevalence, incidence, and mortality of *Plasmodium falciparum*, 2000–17: A spatial and temporal
530 modelling study. *The Lancet*, 394(10195), 322–331. [https://doi.org/10.1016/S0140-6736\(19\)31097-](https://doi.org/10.1016/S0140-6736(19)31097-9)
531 [9](https://doi.org/10.1016/S0140-6736(19)31097-9)
- 532 Whitty, C. J., Chandler, C., Ansah, E., Leslie, T., & Staedke, S. G. (2008). Deployment of ACT antimalarials
533 for treatment of malaria: Challenges and opportunities. *Malaria Journal*, 7(1), S7.
534 <https://doi.org/10.1186/1475-2875-7-S1-S7>
- 535 Willem, L., Verelst, F., Bilcke, J., Hens, N., & Beutels, P. (2017). Lessons from a decade of individual-based
536 models for infectious disease transmission: A systematic review (2006–2015). *BMC Infectious*
537 *Diseases*, 17(1), 612. <https://doi.org/10.1186/s12879-017-2699-8>

- 538 Witkowski, B., Duru, V., Khim, N., Ross, L. S., Saintpierre, B., Beghain, J., Chy, S., Kim, S., Ke, S., Kloeung,
539 N., Eam, R., Khean, C., Ken, M., Loch, K., Bouillon, A., Domergue, A., Ma, L., Bouchier, C., Leang, R.,
540 ... Ménard, D. (2017). A surrogate marker of piperazine-resistant *Plasmodium falciparum* malaria:
541 A phenotype–genotype association study. *The Lancet Infectious Diseases*, 17(2), 174–183.
542 [https://doi.org/10.1016/S1473-3099\(16\)30415-7](https://doi.org/10.1016/S1473-3099(16)30415-7)
- 543 World Health Organization. (2019a). *World Malaria Report 2019* (ISBN: 978-92-4-156572-1; pp. 1–232).
544 World Health Organization. <https://www.who.int/publications/i/item/world-malaria-report-2019>
- 545 World Health Organization. (2019b). *Artemisinin resistance and artemisinin-based combination therapy*
546 *efficacy* (pp. 1–6) [Status Report]. World Health Organization. [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/documents/publications/gmp/who-cds-gmp-2019-17-eng.pdf)
547 [source/documents/publications/gmp/who-cds-gmp-2019-17-eng.pdf](https://www.who.int/docs/default-source/documents/publications/gmp/who-cds-gmp-2019-17-eng.pdf)
- 548 WorldPop. (2018). *Global High Resolution Population Denominators Project* [Map].
549 <https://dx.doi.org/10.5258/SOTON/WP00645>
- 550 Zupko, R., Nguyen, T. D., & Boni, M. F. (2021, September 20). Simulating Human Movement in a National-
551 Scale Individual-Based Model of Malaria in Burkina Faso. *Social Simulation Conference 2021*, Kraków,
552 Poland. <https://mol.ax/pdf/zupko21.pdf>
- 553

554 **Figures**

555 **Fig. 1: Model calibration and validation.** (a) The first point of validation for the model is the comparison
556 of the simulated $PfPR_{2-10}$ values versus the reference $PfPR_{2-10}$ values from the Malaria Atlas Project (Weiss
557 et al. 2019). The annual mean of the simulated $PfPR_{2-10}$ values (light gray dots) are plotted along the y-axis
558 while the reference $PfPR_{2-10}$ is plotted along the x-axis and the closer to agreement (i.e., dashed line) the
559 better. The upper and lower dark gray dots indicate the annual peak and minimum of the seasonal $PfPR_{2-10}$
560 for the given province. (b) Clinical (i.e., symptomatic) cases of malaria plotted against the $PfPR_{2-10}$, for
561 every province. Black dots correspond to every clinical case in the simulation, while gray dots are the
562 clinical cases that would be reported (according to drug coverage numbers). (c) The treatment seeking rate
563 used to inform the model is dependent upon the region of Burkina Faso that an individual is in, with the
564 under-5 treatment rate ranging from a low of 52.1% to a high of 87.0%. Note that the over-5 treatment
565 seeking rate is adjusted to be 45% of the under-5 treatment seeking rate to account for the lower treatment
566 seeking rate in the older demographic. (d) A second point of validation for the model is ensuring that
567 movement is consistent with expected patterns. Heatmap shows the number of trips to the destination cell
568 over the course of a single month in the model. Note that the distribution indicates that while there is always
569 a low chance that an individual may visit any cell, individuals are primarily attracted to major population
570 centers. Subfigure (c) reproduced from Zupko et al. (2021).


571



572
573


574 **Fig. 2: *De novo* emergence of artemisinin resistance under the baseline, status quo scenario.** In the first baseline scenario, C580 is allowed to
575 mutate into 580Y using a mutation rate that has been fit to a previously calibrated pattern of artemisinin resistance in the presence of widespread
576 ACT usage. While the emergence of artemisinin resistance in model year 2021 appears to be stochastic with only minimal evidence of the mutation
577 in the eastern part of the country, by model year 2036 the highest frequencies of artemisinin resistance correspond to areas with persistent
578 transmission and high access to treatment.

580Y Frequency under *de novo* emergence




579

580 **Fig. 3: Comparison of 580Y frequency under various drug policy scenarios.** As expected, increased
581 use of ACTs due to private market elimination results in an increase in the frequency of 580Y under all
582 drug policies. Implementation of MFT results in higher long-term 580Y frequencies due to the high failure
583 rate of PPQ-resistant parasites.




584

585 **Fig. 4: Comparison of treatment failure rates under various policy scenarios.** Under the baseline
586 scenario the treatment failure rate remains fairly consistent year to year. With elimination of the private
587 market, the treatment failure rate drops, which is expected given the elimination of less efficacious
588 treatments. Introduction of MFT plus elimination of the private market has a similar positive outcome;
589 however, this is rapidly offset by the increased treatment failure rate due to the increasing frequency of
590 *plasmepsin-2,3* double-copy genotypes.




591

592 **Fig. 5: Increase of *plasmepsin-2,3* double-copy genotypes under immediate private-market elimination and immediate MFT.** The rapid
 593 elimination of the private market coupled with introduction of MFT (in model year 2021) serves as an exemplar of the rapid increase in double-copy
 594 *plasmepsin-2,3* genotypes after DHA-PPQ is introduced at high levels in 2021. Double-copy *plasmepsin-2,3* genotypes (blue) are strongly selected
 595 for after DHA-PPQ is introduced, which contrasts with the slower pace of 580Y evolution (orange). This rapid increase in the frequency of the
 596 double-copy *plasmepsin-2,3* genotypes result from the low efficacy of DHA-PPQ on these genotypes (77% efficacy on C580 and 42% on 580Y).
 597 KNF genotypes (green) show the most resistance to lumefantrine, but the efficacy of AL on a KNF genotypes is 89% (C580) or 72% (580Y) making
 598 the selection pressure exerted by AL weaker than the selection pressure exerted by DHA-PPQ.




599

600 **Fig. 6: Comparison of *plasmepsin-2,3* double-copy frequency under various drug policies.** Under
601 policies of private market elimination, there is little effect on DHA-PPQ usage and thus low pressure on
602 *plasmepsin-2,3* evolution. When MFT is introduced, the usage of DHA-PPQ increases substantially,
603 resulting in rapid selection of double-copy *plasmepsin-2,3* genotypes.



604

605 **Fig. 7: 580Y frequency under various MFT configurations.** The impact of changing the role of DHA-
606 PPQ in an MFT policy. Lower DHA-PPQ use results in weaker selection pressure on 580Y alleles. The
607 loss of PPQ efficacy due to *plasmepsin-2,3* double-copy emergence is correlated with the rate at which the
608 580Y frequency increases.



609

610 **Table 1. Drug policies examined in this study.** Note that all policy interventions result in a higher 580Y frequency compared to the status quo
611 scenario, but this may be offset by reductions in the treatment failure rate for some policies. Note that the MFT scenarios assume rapid private market
612 (PM) elimination and that unless otherwise specified the MFT is 50% AL and 50% DHA-PPQ.

Drug Policy Studies	580Y Frequency		Treatment Failure Rate	
	Median	IQR	Median	IQR
Status Quo	0.048	0.046 - 0.052	11.57%	11.52% - 11.62%
Rapid AL/DPA-PPQ MFT	0.294	0.283 - 0.307	21.52%	21.27% - 21.66%
Rapid AL/DPA-PPQ MFT, Rapid PM Elimination	0.532	0.513 - 0.545	24.92%	24.58% - 25.14%
Rapid AL/DPA-PPQ MFT, 10 Year PM Elimination	0.471	0.463 - 0.484	23.61%	23.40% - 23.83%
10 Year AL/DPA-PPQ MFT	0.189	0.182 - 0.202	19.47%	19.31% - 19.65%
10 Year AL/DPA-PPQ MFT, Rapid PM Elimination	0.420	0.407 - 0.439	22.62%	22.34% - 22.99%
10 Year AL/DPA-PPQ MFT, 10 Year PM Elimination	0.350	0.340 - 0.362	21.05%	20.82% - 21.25%
Rapid PM Elimination	0.106	0.010 - 0.113	8.88%	8.80% - 8.97%
10 Year PM Elimination	0.085	0.081 - 0.091	8.58%	8.53% - 8.65%
MFT (60% AL, 40% DPA-PPQ)	0.425	0.407 - 0.434	20.46%	20.16% - 20.70%
MFT (70% AL, 30% DPA-PPQ)	0.302	0.288 - 0.311	16.13%	15.93% - 16.27%
MFT (80% AL, 20% DPA-PPQ)	0.178	0.172 - 0.184	12.01%	11.91% - 12.10%
MFT (90% AL, 10% DPA-PPQ)	0.111	0.103 - 0.117	9.14%	9.04% - 9.22%
AL Only, Rapid PM Elimination	0.115	0.109 - 0.119	9.16%	9.09% - 9.21%

613